Last reviewed · How we verify
NCT05840250
Continuous Glucose Monitoring and Diabetes
NA trial testing Continuous Glucose Monitoring and Education Support in Diabetes in 10 participants. Terminated before completion.
14 September 2024
Quick facts
| Lead sponsor | Hackensack Meridian Health |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 10 |
| Start date | 15 May 2023 |
| Primary completion | 14 September 2024 |
| Estimated completion | 14 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Continuous Glucose Monitoring and Education Support
Conditions studied
- Diabetes — all drugs for Diabetes →
Sponsor
Hackensack Meridian Health — full company profile →
Who can join
18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a longitudinal single-arm prospective study design. Adult patients who are African American or Hispanic with type 2 diabetes mellitus will be recruited to participate in this study. The goal of the study is to determine if the use of a continuous glucose monitoring system will improve diabetes management in persons from health disparity background. The subjects will be closely monitored for the first 3 months as they utilize the continuous glucose monitor and engage in diabetes education classes. They will then be followed for an additional 3 months to determine if they are able to maintain the same glucose control as experienced for the initial 3 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05840250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Hackensack Meridian Health trials
Trials by the same sponsor.
- NCT06785402 — Ceftriaxone for Post-Treatment Lyme Disease · Phase 1, PHASE2 · recruiting
- NCT06987708 — Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers · NA · not yet recruiting
- NCT06575894 — Implementing Mental Health Programs Across Communities in Iowa & Indiana for Transformation · NA · not yet recruiting
- NCT07442669 — Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration · NA · not yet recruiting
- NCT06991166 — OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05840250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hackensack Meridian Health
- Last refreshed: 10 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05840250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing